In contrast, in IMpassion031, adding atezolizumab to chemotherapy significantly improved pCR and showed a trend toward better prognosis, although the prognosis improvement was not statistically significant [ 9 ].
← all excerpts
Why combine and why neoadjuvant? Tumor immunological perspectives on chemoimmunotherapy in triple-negative breast cancer.
1
—
—